Abstracts tagged "SLE"

Abstract Number: 2833 • 2014 ACR/ARHP Annual Meeting
SM101, a Novel Recombinant, Soluble, Human FcγIIB Receptor, in the Treatment of Systemic Lupus Erythematosus: Results of a Double-Blind, Placebo-Controlled Multicenter Study
Sascha Tillmanns¹, Claudia Kolligs¹, David P. D'Cruz², Andrea Doria³, Eric Hachulla⁴, Reinhard E. Voll⁵, Michael Tansey¹ and Klaus Schollmeier⁶, ¹Medical/Clinical, SuppreMol GmbH, Martinsried, Germany, ²Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom, ³Department of Medicine - DIMED, University of Padova, Padova, Italy, ⁴Medicine Interne et Oncologie Medicale Centre Pole, Lille University, Lille, France, ⁵Rheumatology and Clinical Immunology & Centre of Chronic Immunodeficiency, University Hospital Freiburg, Freiburg, Germany, ⁶SuppreMol GmbH, Martinsried, Germany
Background/Purpose : SM101, which represents the human soluble non-glycosylated version of the Fcγ receptor IIB, binds to the Fc part of autoimmune complexes and inhibits…
Abstract Number: 2182 • 2014 ACR/ARHP Annual Meeting
Investigating the Roles of Factor H-Related Proteins in Systemic Lupus Erythematosus (SLE) and Other Autoimmune Diseases
Alexandra Antonioli¹, Brandon Renner², Joshua Thurman³, V. Michael Holers⁴ and Jonathan Hannan⁴, ¹Department of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO, ³Renal Division, University of Colorado School of Medicine, Aurora, CO, ⁴Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose Complement plays a central role in the pathogenesis of systemic lupus erythematosus (SLE) wherein inappropriate activation of complement leads to substantial tissue damage, especially…
Abstract Number: 1668 • 2014 ACR/ARHP Annual Meeting
Identifying Patient Perceptions of Medication Decision Making Barriers in Minorities with Lupus Nephritis
Jasvinder A. Singh¹, Haiyan Qu², Jinoos Yazdany³, W. Winn Chatham², Maria Dall'era⁴ and Ricahrd Shewchuk⁵, ¹University of Alabama and VA Medical Center, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵University fo Alabama at Birmingham, Birmingham, AL
Background/Purpose: Studies suggest that adherence to medications for lupus nephritis is low. However, there are limited data available on the barriers that patients with lupus…
Abstract Number: 872 • 2014 ACR/ARHP Annual Meeting
Interferon-α and Angiogenic Dysregulation in Pregnant Lupus Patients Destined for Preeclampsia
Danieli Andrade¹, Mimi Kim², Luz P. Blanco³, S. Ananth Karumanchi⁴, Gloria Koo⁵, Patricia M. Redecha⁶, Kyriakos A. Kirou¹, Angela M. Alvarez⁷, Melissa J. Mulla⁷, Mary K. Crow⁸, Vikki Abrahams⁷, Mariana J. Kaplan³ and Jane E. Salmon⁹, ¹Hospital for Special Surgery, New York, NY, ²Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, ³Systemic Autoimmunity Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁵Autoimmunity & Inflammation, Hospital for Special Surgery, New York, NY, ⁶Rheumatology Research, Hospital for Special Surgery, New York, NY, ⁷Yale School of Medicine, New Haven, CT, ⁸Department of Medicine, Hospital for Special Surgery, New York, NY, ⁹Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Pregnant patients with SLE are at increased risk of placental insufficiency and preeclampsia, disorders associated with angiogenic factor imbalance. IFN-α, a critical element in…
Abstract Number: 669 • 2014 ACR/ARHP Annual Meeting
Predicted Chronic Exposure and Dose Selection for Belimumab Administered Subcutaneously to SLE Patients
Herbert Struemper¹, David Roth² and David Gordon³, ¹GlaxoSmithKline, Research Triangle Park, NC, ²GlaxoSmithKline, Philadelphia, PA, ³Immuno-Inflammation R&D, GlaxoSmithKline, King of Prussia, PA
Background/Purpose: Monthly (q4w) intravenously (IV) administered belimumab 10 mg/kg is approved for the treatment of adults with active, autoantibody-positive SLE receiving standard therapy. The present…
Abstract Number: 2789 • 2014 ACR/ARHP Annual Meeting
Medical Marijuana Related Outcomes in Patients with Systemic Lupus Erythematosis
Basmah Jalil¹, Wilmer Sibbitt Jr.², Romy Cabacangun³, Clifford Qualls⁴, Arthur Bankhurst⁵ and Roderick Fields⁶, ¹Internal Medicine/Rheumatology, University of New Mexico, Albuquerque, NM, ²Internal Medicine/Rheumatology, University of New Mexico HSC, Albuquerque, NM, ³Rheumatology, UNM, Albuquerque, NM, ⁴Biostatistics, UNM, Albuquerque, NM, ⁵Rheum/ MSC 105550, University of NM Med Ctr, Albuquerque, NM, ⁶Internal Medicine/ Rheumatology, University of New Mexico School of Medicine, Albuquerque, NM
Background/Purpose Medical cannabis is used extensively in the United States, usually in the form of smoked marijuana. There is growing research regarding the immunomodulatory effects…
Abstract Number: 2185 • 2014 ACR/ARHP Annual Meeting
Alterations in B Cell Complement Processing Related to a Lupus-Associated Variant in Complement Receptor 2
Brendan M. Giles¹ and Susan A. Boackle², ¹University of Colorado School of Medicine, Aurora, CO, ²Medicine/Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: We have recently identified a variant in intron 1 of complement receptor 2 (CR2/CD21) that is associated with decreased risk of lupus (rs1876453; Pmeta=4.2×10-4,…
Abstract Number: 1664 • 2014 ACR/ARHP Annual Meeting
Novel Risk Factors for Systemic Lupus Erythematosus (SLE) Flares in Patients with End-Stage Renal Disease: Is SLE in Patients with End-Stage Renal Disease a “sleeping beauty”?
Jorge Alcocer-Varela¹, Mariana Quintanar², Javier Merayo-Chalico³, Ana Barrera-Vargas¹ and Diana Gómez-Martín¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose Renal involvement in systemic lupus erythematosus (SLE) is frequent, and a high percentage of patients (~15%) develop end-stage renal disease (ESRD) even with optimal…
Abstract Number: 870 • 2014 ACR/ARHP Annual Meeting
IRF1 Influences on Histone H4 Acetylation in Systemic Lupus Erythematosus
Yiu Tak Leung¹, Lihua Shi², Kelly Maurer², Li Song², Zhe Zhang³, Michelle Petri⁴ and Kathleen E. Sullivan², ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA, ³Bioinformatics, Bioinformatics, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is the classical systemic autoimmune disease. Epigenetic processes, such as posttranslational histone modifications, can regulate gene expression without altering the…
Abstract Number: 668 • 2014 ACR/ARHP Annual Meeting
Evolution of Patients with Systemic Lupus Erythematous Treated with Belimumab in Clinical Practice Settings
Josefina Cortes¹, Carlos Marras², Jose Luis Andreu³, Jaime Calvo-Alen⁴, Angel M. Garcia-Aparicio⁵, Elvira Diez Alvarez⁶, Carlos Coronell⁷, Elena Morejon⁷, Alessandra Perna⁸, Volker Koscielny⁸ and Josep Ordi-Ros¹, ¹Internal Medicine, Vall d´Hebron Hospital, Barcelona, Spain, ²Rheumatology, Virgen de la Arrixaca Hospital, Murcia, Spain, ³Rheumatology, Puerta de Hierro Universitary Hospital, Madrid, Spain, ⁴Rheumatology Division, Sierrallana Hospital, Torrelavega, Spain, ⁵Rheumatology, Virgen de la Salud Hospital, Toledo, Spain, ⁶Rheumatology, Leon Hospital, Leon, Spain, ⁷Medical Department, GlaxoSmithKline, Madrid, Spain, ⁸Medical Department, GlaxoSmithKline, Brentford, United Kingdom
Background/Purpose After the approval of belimumab for patients with systemic lupus erythematosus (SLE), the objective of this study is to describe the clinical outcomes associated…
Abstract Number: 2791 • 2014 ACR/ARHP Annual Meeting
Lung Cancer in SLE
Sasha Bernatsky¹, Rosalind Ramsey-Goldman², Michelle Petri³, Murray B. Urowitz⁴, Dafna D. Gladman⁴, Edward H. Yelin⁵, Christine Peschken⁶, John G. Hanly⁷, James E. Hansen⁸, Jean-Francois Boivin⁹, Lawrence Joseph¹⁰, Patrice Chrétien Raymer¹¹, Mruganka Kale¹², Ann E. Clarke¹³ and Systemic Lupus International Collaborating Clinics (SLICC)¹⁴, ¹Clinical Epidemiology - Rheumatology, McGill University, Montreal, QC, Canada, ²FSM-300, Northwestern University, Chicago, IL, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Arthritis Research Group, University of California, San Francisco, San Francisco, CA, ⁶Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ⁷Division of Rheumatology, Dalhousie University and Capital Health, Halifax, NS, Canada, ⁸Therapeutic Radiology, Yale University, New Haven, CT, ⁹Department of Epidemiology & Biostatistics, McGill University, Montreal, QC, Canada, ¹⁰McGill University, Montreal, QC, Canada, ¹¹Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ¹²Clinical Epidemiology Rheum, RI McGill Univ Health Ctr, Montreal, QC, Canada, ¹³Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ¹⁴Systemic Lupus International Collaborating Clinics (SLICC), ON, Canada
Background/Purpose: Lung cancer is 50% more common in SLE patients than their sex and age-matched counterparts. Our objective was to assess lung cancer risk in…
Abstract Number: 2166 • 2014 ACR/ARHP Annual Meeting
Bim Suppresses the Development of Glomerulonephritis By Inhibiting M2 Polarization
Fu-Nien Tsai, Northwestern University, Chicago, IL
Background/Purpose Only recently have monocytes and macrophages been accepted as critical players in the pathogenesis of SLE. However, very little is known regarding the molecular…
Abstract Number: 1650 • 2014 ACR/ARHP Annual Meeting
Prevalence and Prognostic Implications of IgG4 in Membranous Lupus Nephritis
David Herrera Van Oostdam¹, Marco Ulises Martinez-Martinez¹, Cuauhtémoc Oros-Ovalle², David Martínez-Galla², Gerardo Tonatiu Jaimes-Piñón¹, Natalia Alemán-Sánchez² and Carlos Abud-Mendoza¹, ¹Unidad de Investigaciones Reumatológicas, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ²Patología, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico
Background/Purpose: Patients with membranous lupus nephritis (MLN) have increased risk of thrombosis and different prognosis than other classes of lupus nephritis (LN). Previous studies demonstrated…
Abstract Number: 867 • 2014 ACR/ARHP Annual Meeting
Specific SLE Disease Manifestations in the Six Months Prior to Conception Predict Similar Manifestations during Pregnancy
Sara K. Tedeschi¹, Hongshu Guan¹, Alexander Fine¹, Bonnie L. Bermas² and Karen H. Costenbader², ¹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Active SLE, in particular lupus nephritis, during the six months prior to conception is associated with disease flare during pregnancy. Previous studies, however, have…
Abstract Number: 657 • 2014 ACR/ARHP Annual Meeting
Distinct Contributions of C1q and C3 in Preventing Immunogenicity of Apoptotic Cells in Lupus
Clayton Sontheimer¹, Yenly Nguyen², Keith B. Elkon³ and YuFeng Peng³, ¹Pediatric Rheumatology, University of Washington, Seattle, WA, ²University of Washington, Seattle, WA, ³Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Defective clearance of apoptotic cells (AC) and complement deficiency are important contributors to the pathogenesis of systemic lupus. Dead (sunburn) cells and complement…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].